Editors of The Lancet issued an "expression of concern" Jan. 17 about a study published in the journal in October which appeared to be based on "complete fabrication" by the study's lead author. John Sudbo, MD, PhD, Norwegian Radium Hospital, et al., found in a study that long-term use of NSAIDs was linked to reduced incidence of oral cancer but increased risk of death from cardiovascular disease. The hospital alerted Lancet editors to the problem Jan. 13, and the publication states that "the journal has not yet received written confirmation...that fabrication actually took place." The hospital has appointed an investigation committee to look into the matter. Sudbo's findings were first presented at the American Association for Cancer Research annual meeting in April (1"The Tan Sheet" April 25, 2005, p. 10)...

Lack of official explanation about how the exchange of critical information will progress pending the launch of the EU’s medical device database, Eudamed3, has left many confused. New guidance lights the way forward.

From relatively little-known to high-flying, hotly pursued targets by global pharma players, Chinese domestically developed immuno-oncology drugs are ascending in both value and attractiveness, both inside China and far beyond.